Biotek-snakken — Maj 2022
-
Men de er desværre blevet enige om det 2,20. Meget sørgeligt synes jeg, og går desværre glip af en kæmpe gevinst
IPO tilbage i 2018 var USD15, og nu når selskabet står foran at file NDA på SUL-DUR, ja så løber INVA med guldet (man kan selvfølgelig købe aktier i INVA). Skuffet..ja absolut. https://endpts.com/at-the-cusp-of-nda-filing-for-lead-antibiotic-astrazeneca-spinout-goes-private-at-a-fraction-of-ipo-price/ -
Nogen herinde der følger Vicore Pharma? Et par pæne anbefalinger på det sidste…. 17-05-2022
STOCKHOLM (Nyhetsbyrån Direkt) Nordea Markets tar upp bevakning av Vicore Pharma med rekommendationen köp och en riktkurs på 84 kronor.Det framgår av en analys.
Aktien stängde på 18:68 kronor på måndagen.
-
STOCKHOLM (Nyhetsbyrån Direkt) Redeye höjer sitt riktvärde för Vicore Pharma i basscenariot till 75 kronor från tidigare 64 kronor.
Det framgår av en analys.
Bakgrunden till höjningen, skriver Redeye, ligger till stor del i stark data inom projektet C21 vid behandling av idiopatisk lungfibros (IPF). Redeye uppger sig även se ett ökat förtroende för bolagets portfölj.
Regulatorisk vägledning inom IPF och ytterligare interimsdata uppges vara viktiga kurstriggers.
Vicore-aktien var under måndag
-
RAPT Therapeutics Announces Private Placement Financing of $50 Million
SOUTH SAN FRANCISCO, Calif., May 25, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced a $50 million private investment in public equity (PIPE) financing from the sale of pre-funded warrants to purchase up to 4 million shares of its common st
Yahoo Finance (finance.yahoo.com)
-
This Mid-Cap Firm Can Potentially Offer Biggest Oral Drug In Atopic Dermatitis, Cantor Thinks So
Cantor assumes coverage of RAPT Therapeutics Inc (NASDAQ: RAPT) with an Overweight rating and a price target of $44 (vs. $58 previously). The analyst says the company's RPT193 (lead inflammation drug) could be a $3 billion drug in just atopic dermatitis (AD) indication, as it expects AD to outperform psoriasis. Cantor suggests that ‘193 is the leading oral drug in mid-to late-stage development with use in a broader population (not limited to refractory patients like JAKs) and with a clean safety
Yahoo Finance (finance.yahoo.com)
-
Zymeworks - dejligt med lidt gode nyheder for Zanidatamab. https://finance.yahoo.com/news/clinical-data-demonstrating-promising-antitumor-210000234.html
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind